Skip to content
DataLookout
Menu

NCT07426380

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 12 words
    • Trial completed
    • Primary and study completion dates changed from estimate of Oct 2026 to Oct 6, 2026
  2. Minor Enrollment closed, study ongoing
    • Site details revised at 2 of 2 sites
    v5
  3. Minor Site details revised at 1 of 2 sitesv4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2026 to Feb 24, 2026
    • Site details revised at 2 of 2 sites
    v3
  5. Minor Study title revisedv2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136
Timeframe: Predose on Day 1 up to Day 71
PK: Maximum Observed Drug Concentration (Cmax) of LY3841136
Timeframe: Predose on Day 1 up to Day 71

Arms and interventions

Eloralintide (Group 1)Experimental

Eloralintide administered subcutaneously (SC) in a control group of participants with normal renal function

Eloralintide (Groups 2 and 3)Experimental

Eloralintide administered SC in groups of participants with impaired renal function

Eloralintide (Group 3)Experimental

Eloralintide administered SC in a group of participants with end-stage renal disease (ESRD) on stable hemodialysis

Drugs: LY3841136

Sites

2 sites in 1 country